KMT2A and leukemia: Small molecule menin inhibitors (MIs), including MI‐463 and MI‐503, were developed to target this pocket and block the menin–MLL interaction, and MIs are effective at suppressing MLL‐fusion protein‐induced leukemia in vivo (Borkin et al,2015).